Persistently elevated expression of systemic, soluble co-inhibitory immune checkpoint molecules in people living with HIV before and one year after antiretroviral therapy

Loading...
Thumbnail Image

Authors

Labuschagne Naidoo, Robyn-Brooke
Steel, Helen C.
Theron, Annette J.
Anderson, Ronald
Tintinger, Gregory Ronald
Rossouw, Theresa M.

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI

Abstract

Please read abstract in article.

Description

DATA AVAILABILITY STATEMENT: The data that support the findings of this study are available from the corresponding author upon reasonable request.
SUPPORTING INFORMATION: TABLE S1: Comparison of soluble immune checkpoint levels between female and male PLWH before ART; TABLE S2: Comparison of soluble immune checkpoint levels between female and male PLWH after 12 months of ART; TABLE S3: Comparison of the change in soluble immune checkpoint levels before and after 12 months of ART between tobacco-users and non-users; TABLE S4: Correlations between age and soluble immune checkpoint molecules before treatment in PLWH.

Keywords

Antiretroviral treatment, Co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1, PD-L1, TIM-3, SDG-03: Good health and well-being, SDG-09: Industry, innovation and infrastructure, Antiretroviral therapy (ART), Human immunodeficiency virus (HIV)

Sustainable Development Goals

SDG-03:Good heatlh and well-being
SDG-09: Industry, innovation and infrastructure

Citation

Labuschagne Naidoo, R.-B.; Steel, H.C.; Theron, A.J.; Anderson, R.; Tintinger, G.R.; Rossouw, T.M. Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy. Pathogens 2024, 13, 540. https://doi.org/10.3390/pathogens13070540.